Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 14-20

  Chen, Chung Hsin ^a   Dickman, Kathleen G ^b   Huang, Chao Yuan ^a   Moriya, Masaaki ^b   Shun, Chia Tung ^a   Tai, Huai Ching ^a   Huang, Kuo How ^a   Wang, Shuo Meng ^a   Lee, Yuan Ju ^a   Grollman, Arthur P ^b   Pu, Yeong Shiau ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

aristolochic acid; p53; renal pelvis; transitional cell carcinoma; ureter

Indexed keywords

ADENOSINE; ARISTOLOCHIC ACID; CYTIDINE; PROTEIN P53; URACIL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGEN TESTING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; FEMALE; GENE SEQUENCE; HUMAN; KIDNEY CORTEX; MALE; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NUCLEIC ACID BASE SUBSTITUTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TAIWAN; TP53 GENE; TRANSITIONAL CELL CARCINOMA;

ADENINE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARISTOLOCHIC ACIDS; CARCINOGENS; CARCINOMA, TRANSITIONAL CELL; DNA ADDUCTS; DNA, NEOPLASM; DRUGS, CHINESE HERBAL; FEMALE; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MUTAGENS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; RECURRENCE; RISK FACTORS; SEQUENCE ANALYSIS, DNA; SEX FACTORS; TAIWAN; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; UROLOGIC NEOPLASMS;

EID: 84876664185     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28013     Document Type: Article

References (34)

1. Hsieh SC, Lin IH, Tseng WL, et al. Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med 2008; 3: 13-18.
2. Chinese Company of Medicinal Materials [CMM (1995)]. China medicinal herbs most in use. Beijing: Science publishing house, 1995. 838-39.
3. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341: 387-91.
4. Pena JM, Borras M, Ramos J, et al. Rapidly progressive interstitial renal fibrosis due to a chronic intake of a herb (Aristolochia pistolochia) infusion. Nephrol Dial Transplant 1996; 11: 1359-60.
5. Cronin AJ, Maidment G, Cook T, et al. Aristolochic acid as a causative factor in a case of Chinese herbal nephropathy. Nephrol Dial Transplant 2002; 17: 524-5.
6. Grollman AP, Shibutani S, Moriya M, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A 2007; 104: 12129-34.
7. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-92.
8. Belicza M, Demirovic A, Tomic K, et al. Comparison of occurrence of upper urinary tract carcinomas in the region with endemic villages and non-endemic nephropathy region in Croatia. Coll Antropol 2008; 32: 1203-7.
9. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 2010; 102: 179-86.
10. Jelakovic B, Karanovic S, Vukovic-Lela I, et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012; 81: 559-67.
11. Schmeiser HH, Bieler CA, Wiessler M, et al. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996; 56: 2025-8.
12. Feldmeyer N, Schmeiser HH, Muehlbauer KR, et al. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat Res 2006; 608: 163-8.
13. Liu Z, Hergenhahn M, Schmeiser HH, et al. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A 2004; 101: 2963-8.
14. Moriya M, Slade N, Brdar B, et al. TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 2011; 129: 1532-6.
15. Chen CH, Chiou HY, Hsueh YM, et al. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan. J Urol 2009; 181: 547-52.
16. Fairchild WV, Spence CR, Solomon HD, et al. The incidence of bladder cancer after cyclophosphamide therapy. J Urol 1979; 122: 163-4.
17. Matanoski GM, Elliott EA,. Bladder cancer epidemiology. Epidemiol Rev 1981; 3: 203-29.
18. Chen CH, Dickman KG, Moriya M, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012; 109: 8241-6.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
20. Eble JN, Sauter G, Epstein JI, et al. WHO classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004. 117-8.
21. UICC. TNM classification of malignant tumors, 6th edn. New York: Wiley, 2002. 219-22.
22. Maniatis T, Fritsch EF, Sambrook J,. Biochemical techniques. Molecular cloning (A laboratory manual), Chapter appendix A. Cold Spring Harbor NY: Cold Spring Harbor Laboratory, 1982. 458-61.
23. Dong H, Suzuki N, Torres MC, et al. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/ polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 2006; 34: 1122-7.
24. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
25. Cukuranovic R, Ignjatovic I, Visnjic M, et al. Characteristics of upper urothelial carcinoma in an area of Balkan endemic nephropathy in south Serbia. A fifty-year retrospective study. Tumori 2010; 96: 674-9.
26. Raman JD, Messer J, Sielatycki JA, et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int 2011; 107: 1059-64.
27. Chromecki TF, Cha EK, Fajkovic H, et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol 2012; 61: 245-53.
28. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2010. Lyon, France: International Agency for Research on Cancer.
29. Bureau of Health Promotion DoHT. The incidence of renal pelvic and ureteral tumor in Taiwan. Available at: https://cris.bhp.doh.gov.tw/pagepub/ Home.aspx?itemNo=cr.q.10, accessed September, 2012.
30. Wang JD,. Establishment of an active surveillance system for Chinese herbal medicine. Yearbook Chinese Medicine and Pharmacy 2006; 24: 157-280.
31. Lai MN, Lai JN, Chen PC, et al. Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study. Am J Kidney Dis 2010; 55: 507-18.
32. Chang CH, Yang CM, Yang AH,. Renal diagnosis of chronic hemodialysis patients with urinary tract transitional cell carcinoma in Taiwan. Cancer 2007; 109: 1487-92.
33. Holmang S, Johansson SL,. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol 2006; 175: 69-72.
34. Huang PC, Huang CY, Huang SW, et al. High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan. Int J Urol 2006; 13: 864-9.